首页> 外文OA文献 >A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

【2h】

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

机译：GTI-2040加多西紫杉醇作为晚期非小细胞肺癌二线治疗的I / II期研究：PMH II期联合体的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Leighl Natasha B.; Laurie Scott A.; Chen Xueyu E.; Ellis Peter; Shepherd Frances A.; Knox Jennifer J.; Goss Glenwood; Burkes Ronald L.; Pond Gregory R.; Dick Christopher; Yen Yun; Zwiebel James A.; Moore Malcolm J.;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium. [J] . Leighl NB, Laurie SA, Chen XE, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2009,第9期

机译：GTI-2040联合多西紫杉醇作为晚期非小细胞肺癌二线治疗的I / II期研究：PMH II期联合体的研究。
2. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. [J] . J V Heymach, S J Lockwood, R S Herbst, Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第10期

机译：在一项晚期非小细胞肺癌患者二线治疗的随机III期研究中，EGFR生物标记物预测了Vandetanib与docetaxel联用的益处。
3. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. [J] . J V Heymach, S J Lockwood, R S Herbst, Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第10期

机译：EGFR生物标志物预测Vandetanib的益处与多西紫杉醇组合在随机的非小细胞肺癌患者的二线治疗的随机期III研究中。
4. PHASE II OPEN-LABEL STUDY OF SINGLE-AGENT HYDROXYUREA FOR TREATMENT OF ADVANCED CUTANEOUS MAST CELL TUMORS IN DOGS [C] . Ken Rassnick, Renee Al-Sarraf, Dennis Bailey, Annual Conference of the Veterinary Cancer Society . 2009

机译：单药羟基脲的第II期开放标签研究，用于治疗犬晚皮腰肿瘤瘤
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC). A study of the PMH Phase II Consortium [O] . NB Leighl, SA Laurie, XE Chen, -1

机译：GTI-2040加多西紫杉醇作为先进非小细胞肺癌（NSCLC）的二线治疗的I / II类研究。 PMH第二阶段联盟的研究
7. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer [O] . J.V. Heymach, S.J. Lockwood, R.S. Herbst, 2014

机译：EGFR Biomarkers预测Vandetanib的益处与多西紫杉醇组合在随机的非小细胞肺癌患者的二线治疗的随机期III研究中

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

著录项

引文网络

相似文献

相关主题

期刊订阅